The recent discovery of a dysfunctional mutation of GPIHBP1 in a man with chylomicronemia implicates this protein in human physiology. GPIHBP1 can be placed in the larger context of other molecular participants in chylomicron docking and hydrolysis on microvascular endothelium, caloric delivery, and remnant lipoprotein generation. Critical questions include the regulation-and dysregulation-of these processes in states of overnutrition, underexertion, obesity, insulin resistance, and diabetes.
F or decades, we were convinced that heparan sulfate proteoglycans (HSPGs) on the microvascular endothelium of adipose tissue and striated muscle served as the docking site for chylomicrons (CMs) during their lipolysis by lipoprotein lipase (LpL). 1 A serendipitous observation of milky plasma in GPIHBP1-deficient mice and its skillful elucidation by the Young laboratory implicate this molecule instead. 2, 3 The work represents a major revision in our understanding of lipoprotein-mediated caloric delivery. In the current issue of ATVB, Beigneux et al report a novel dysfunctional missense mutation in GPIHBP1 that they found in a chylomicronemic man, thereby extending the relevance of their findings to humans. 4
See accompanying article on page 956
The physiological role of GPIHBP1 was not found by cloning the protein, which was originally identified as an HDLbinding molecule, hence its name. 5 Nor was its role revealed by sequencing the human genome, nor by any genome-wide association studies. 6 Cell culture also failed, 7-10 because endothelial cells promptly lose expression of GPIHBP1 in vitro. 11 The Figure presents a recent attempt to place GPIHBP1 in the larger context of other molecular participants in CM docking, hydrolysis, caloric delivery, and remnant lipoprotein generation. 12 Some of these molecules, such as caveolin-1 13, 14 and CD36, 15, 16 have been implicated in mice and humans in vivo. But some processes, such as HSPG-mediated endocytosis and destruction of LpL by adipocytes 17, 18 and transendothelial transport of LpL by HSPGs and the VLDL receptor, 19 have been documented only in vitro.
Nevertheless, the available evidence suggests that key molecular participants share crucial features of location and regulation. Regarding location, hydrolysis of CM triglyceride and then tissue uptake of nonesterified fatty acids (NEFAs) may be facilitated by being concentrated within cholesterolrich membrane microdomains, also known as rafts. 12 The major HSPGs of endothelial cells include the transmembrane syndecans and the GPI-anchored glypicans. Syndecan HSPGs move laterally into rafts on clustering, 20, 21 and binding a dimer of LpL, the enzymatically active form, appears to be a sufficient trigger. 20 GPI-anchored molecules also move into rafts on clustering. 22 Thus, syndecans, glypicans, and GPI-HBP1 should come into close proximity within rafts after the transendothelial transport of dimeric LpL, thereby facilitating the transfer of this enzyme from HSPGs onto higher-affinity binding sites on GPIHBP1. Likewise, the CD36 fatty acid translocase also localizes to rafts, 23 which could facilitate its ability to accept NEFAs from LpL-GPIHBP1-CM complexes during triglyceride hydrolysis ( Figure) . Consistent with this model, knock-out of caveolin-1, a scaffolding molecule required for the formation of certain types of cholesterol-rich microdomains, impairs lipolysis of postprandial lipoproteins and the importation of NEFAs into adipose tissue. 13 Similar effects have been associated with a nonsense mutation of human caveolin-1. 14 To complete this picture, we need to address several additional questions. What molecules mediate transendothelial transport of LpL in vivo? Endothelium does not make LpL, but must acquire it from underlying adipocytes and myocytes. As noted above, cell-culture data implicate HSPGs and the VLDL receptor. The VLDL receptor was reported to affect LpL regulation in vivo, possibly related to transendothelial transport. 24 If HSPGs are involved in vivo, which ones? Syndecans-1, -2, and -4 and glypican-1 would be attractive candidates, owing to their expression by cultured endothelial cells 25, 26 and their ability to directly mediate ligand internalization. 20, 21, [27] [28] [29] Syndecans bind LpL in vitro 20, 27 and mediate endocytosis via rafts. 20, 30 Glypican-1 undergoes caveolar-associated recycling, 28 and digestion of cultured adipocytes and myocytes with phosphatidylinositolspecific phospholipase-C releases HSPG-bound LpL, [31] [32] [33] although digestion of cultured endothelial cells did not. 10 Thus, under some circumstances, syndecans and glypicans function as LpL receptors in vitro, but their role in LpL trafficking across the endothelium in vivo remains unknown.
Could GPIHBP1 be involved in transendothelial transport of LpL? It seems unlikely, given its apparently exclusive expression on the luminal surface. 2 But why, then, is the amount of LpL released into postheparin plasma affected by a deficiency of functional GPIHBP1, even though tissue stores of the enzyme remain normal? 34 Plasma levels of LpL were low at early, but not later, time points after a heparin injection into GPIHBP1-deficient mice, 34 and LpL was low in a single sample of postheparin plasma from the individual with the dysfunctional missense mutation. 4 In addition, GPI-HBP1 deficiency blocked the release of LpL into plasma at all time points tested after an injection of artificial triglyceride emulsion particles. 34 There may be two pools of LpL, one displayed on luminal GPIHBP1 and one deep within adipose tissue and striated muscle. 34 Both pools might be eventually accessible to heparin, which has been reported to readily pass through arterial endothelium, 35 but only the pool adherent to GPIHBP1 would be accessible to emulsions and able to hydrolyze lipoprotein triglyceride. On the other hand, because heparin inhibits transendothelial transport of LpL in vitro, 19 heparin that reaches the tissue pool of LpL might strand it there, rather than facilitating its release into plasma. Moreover, delayed release of nonluminal depots of LpL has been documented from hearts perfused with heparin, but the mechanism implicated in that study was the gradual transport of this enzyme to the endothelial surface, after Figure. Integrated model of CM binding and hydrolysis on peripheral capillary endothelium. Adipose tissue and striated muscle each synthesize LpL, regulated by the fasted/fed and active/sedentary metabolic states. HSPGs on the surfaces of these cells capture and internalize LpL for degradation. LpL that escapes degradation will be picked up by HSPGs and VLDL receptors on the basal surface of overlying endothelial cells for transcytosis to the luminal surface of capillaries (orange arrows). Heparan sulfate side-chains of syndecan and glypican are denoted by chains of small spheres. The major HSPGs of endothelium, syndecans and glypicans, move into detergent-insoluble membrane microdomains (rafts) rich in caveolin-1 (CAV1) upon clustering. On the apical surface, they encounter GPIHBP1, which should also move into rafts upon clustering. The highly negatively charged N-terminal domain of GPIHBP1 binds LpL with approximately 10-fold greater affinity than do endothelial HSPGs. Thus, after transcytosis, LpL should be torn away from syndecans and glypicans onto GPIHBP1 (pink arrows). Dimers of GPIHBP1 bind LpL and CMs, thereby providing a platform for CM docking and triglyceride lipolysis. These processes are facilitated by apoC-II and apoA-V. Lipolysis generates NEFAs that are transported by another raft molecule, CD36, across the endothelium and into adipocytes for energy storage (blue arrows) or into striated myocytes for combustion (green arrows). After hydrolysis of CM triglycerides, the endothelium releases apoB 48 remnant lipoproteins that are rich in LpL, apoE, and cholesteryl ester back into the circulation (red arrow). Under normal circumstances, these remnant particles undergo safe swift uptake by the liver. Reprinted. 12 which it was nearly immediately released by heparin in the perfusate. 36 Alternatively, if transfer of LpL from endothelial HSPGs and VLDL receptors onto GPIHBP1 does in fact occur, it could prevent HSPG-or VLDL receptor-mediated endocytosis or transcytosis back into the subendothelial space, particularly if those molecules continuously recycle. Evidence in vivo indirectly supports the existence of a pool of LpL molecules that recirculate between the luminal surface of the endothelium and extravascular sites in adipose tissue. 37 Cultured endothelial cells also internalize LpL and then recycle it back to the cell surface intact. 17, 33, 38 Here, the model presumes that LpL cycling back and forth across the luminal endothelial membrane remains inaccessible to triglyceride-rich lipoproteins and emulsion particles in the bloodstream, unless the enzyme can move onto GPIHBP1. As a speculative example, LpL bound to the heparan sulfate side-chains of glypican would sit close to the plasma membrane (Figure) , where very large particles might not be able to approach. 39 Does GPIHBP1 affect the enzymatic activity of LpL? It has long been know that heparin-induced release of LpL from its binding sites on the luminal surface of endothelium quickly accelerates the hydrolysis of triglyceride-rich lipoproteins in plasma in vivo. 1, 34, 40, 41 It could simply be a matter of better access to substrate when the enzyme is in solution than when it is confined to a surface, but it is also possible that the conformation of LpL is altered by its association with GPIHBP1. If the latter, the conformational changes could be regulated.
What physical determinants allow remnant lipoproteins and artificial emulsions to acquire LpL from the luminal surface of the endothelium? In normal physiology, the shift in apoprotein composition before CM docking (apoB 48 , apoA-V, apoC-II, apoE) versus after remnant release (apoB 48 , LpL, apoE) sets the stage for rapid hepatic uptake via the unusual, highly charged HSPGs that are displayed on the basal surface of healthy hepatocytes 12, 27, [42] [43] [44] (Figure) . Postprandial apoB 48 -containing lipoproteins that contain LpL are cleared from human plasma much faster than particles without this important molecule, 45 consistent with the earlier suggestion that LpL should be regarded as an apoprotein whose function is recognition by hepatic HSPGs. 27, 42 Do changes in particle size and composition during lipolysis enhance adsorption of LpL? A role for apoB 48 seems unlikely, because artificial triglyceride emulsions acquire LpL in vivo in wild-type animals, 46 consistent with wellestablished physical properties of the enzyme. 1, 47 Do GPIHBP1 or other proteins alter their conformations to facilitate LpL release to remnants or emulsions during lipolysis? Generation of NEFAs in excess of tissue importation appears to be a physiological stimulus for the release of LpL from endothelium in vivo, thereby slowing local lipolysis. 48 Thus, NEFAs may be one factor to dissociate LpL-GPIHBP1 complexes.
But the most interesting questions relate to human physiology and pathophysiology. Fasting, high-fat feeding, and PPAR␥ activation increase Gpihbp1 mRNA levels in white adipose tissue, brown adipose tissue, and striated muscle of mice, consistent with a role in directing caloric delivery. 11 If differential regulation of the GPIHBP1 protein among these tissues is found, then it would join an important list of molecules that control the metabolic branch point between delivery of CM triglycerides into white adipose tissue for storage, versus uptake into brown adipose tissue and striated muscle for combustion. 12, 49 The regulation-or dysregulation-of these molecules in states of overnutrition, underexertion, obesity, insulin resistance, diabetes, and related conditions is becoming an increasingly significant medical issue.
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